Literature DB >> 23528309

Cloning of variable fragments of tumor immunoglobulin, assembling and expressing of human SCFV protein in E. coli for anti-idiotype vaccination.

A N Meleshko1, K P Vashkevich, E G Fomina, E P Scheslenok, T V Schkolina, G V Sergeev.   

Abstract

AIM: Idiotype, the unique part of immunoglobulin molecule expressed on the surface of B-cells, represents a specific antigen for vaccination against lymphoma. We have developed a rapid method for immunoglobulin variable fragments cloning, assembling and expression of recombinant idiotype protein in Escherichia coli.
METHODS: PCR with specially designed panel of primers was used for direct amplification of variable regions of tumor immunoglobulin. Overlapping extension PCR, restriction and ligation was applied for assembling and cloning of vaccine construction. Idiotype protein was purified by metal-chelate chromatography.
RESULTS: Methods of idiotype cloning from lymphoma cells and production of recombinant protein were developed and optimized. Several samples of idiotypic proteins originating from B-cell lines and lymphoma patients were produced.
CONCLUSION: The proposed method of vaccine production is relatively cheap, not very laborious and requires as long as 6-7 week to perform. The expressed protein was soluble, did not accumulate in inclusion bodies and harvested at sufficient for vaccination quantity and concentration.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23528309

Source DB:  PubMed          Journal:  Exp Oncol        ISSN: 1812-9269


  3 in total

1.  Phase I clinical trial of idiotypic DNA vaccine administered as a complex with polyethylenimine to patients with B-cell lymphoma.

Authors:  A N Meleshko; N A Petrovskaya; N Savelyeva; K P Vashkevich; S N Doronina; N V Sachivko
Journal:  Hum Vaccin Immunother       Date:  2017-03-08       Impact factor: 3.452

2.  Specific Targeting of Lymphoma Cells Using Semisynthetic Anti-Idiotype Shark Antibodies.

Authors:  Arturo Macarrón Palacios; Julius Grzeschik; Lukas Deweid; Simon Krah; Stefan Zielonka; Thies Rösner; Matthias Peipp; Thomas Valerius; Harald Kolmar
Journal:  Front Immunol       Date:  2020-11-26       Impact factor: 7.561

3.  Safety and Immunogenicity of Combined DNA-Polyethylenimine and Oral Bacterial Idiotypic Vaccine for Patients with B-Cell Non-Hodgkin Lymphoma: A Pilot Study.

Authors:  Alexander Meleshko; Nadzeya Piatrouskaya; Katsiaryna Vashkevich; Dzmitry Lutskovich; Chuan Wang; Dmitri Dormeshkin; Natalia Savelyeva; Mikalai Katsin
Journal:  Cancers (Basel)       Date:  2022-07-06       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.